Floatz logo

186 assets in Her2-Receptor Negative Breast Cancer

Therapeutic assets addressing Her2-Receptor Negative Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Palbociclib
Her2-Receptor Negative Breast Cancer
Helwan UniversityP2BBB (75)
Exemestane
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P4BBB (73)
Pembrolizumab
Her2-Receptor Negative Breast Cancer
UNC Lineberger Comprehensive Cancer CenterP2BBB (72)
Atezolizumab
Her2-Receptor Negative Breast Cancer
TransThera Sciences (Nanjing), Inc.P2BB (69)
Capecitabine
Her2-Receptor Negative Breast Cancer
Kristina A. FanucciP4BB (68)
Docetaxel
Her2-Receptor Negative Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P2/3BB (68)
Durvalumab
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P3BB (68)
Palazestrant
Her2-Receptor Negative Breast Cancer
Olema Pharmaceuticals, Inc.P3BB (68)
Benzamide, N-[(3R)-3-(2-Chloro-5-Fluorophenyl)-6-(5-Cyano[1,2,4]Triazolo[1,5-A]Pyridin-6-Yl)-2,3-Dihydro-1-Oxo-1H-Isoindol-4-Yl]-3-Fluoro-5-(Trifluoromethyl)-
Her2-Receptor Negative Breast Cancer
Relay Therapeutics, Inc.P3BB (66)
Capivasertib
Her2-Receptor Negative Breast Cancer
West German Study GroupP3BB (66)
Fulvestrant
Her2-Receptor Negative Breast Cancer
Olema Pharmaceuticals, Inc.P4BB (66)
Irinotecan
Her2-Receptor Negative Breast Cancer
GI Innovation, Inc.P4BB (66)
Cediranib
Her2-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterP2BB (65)
Elacestrant
Her2-Receptor Negative Breast Cancer
Kristina A. FanucciP3BB (65)
Ribociclib
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P4BB (65)
Adriamycin
Her2-Receptor Negative Breast Cancer
George Washington UniversityP4BB (64)
Anastrozole
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P4BB (64)
Epirubicin
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2/3BB (64)
Everolimus
Her2-Receptor Negative Breast Cancer
MedSIRP4BB (64)
Ixabepilone
Her2-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterP3BB (64)
Letrozole
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P4BB (64)
Talazoparib
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P2BB (64)
Tamoxifen
Her2-Receptor Negative Breast Cancer
University of ChicagoP4BB (64)
Abemaciclib
Her2-Receptor Negative Breast Cancer
Jonsson Comprehensive Cancer CenterP4B (63)
Goserelin
Her2-Receptor Negative Breast Cancer
Memorial Sloan Kettering Cancer CenterP4B (63)
Nivolumab
Her2-Receptor Negative Breast Cancer
Fred Hutchinson Cancer CenterP2B (63)
Trastuzumab Emtansine
Her2-Receptor Negative Breast Cancer
University of ChicagoP2B (63)
Carboplatin
Her2-Receptor Negative Breast Cancer
Fudan UniversityP3B (62)
Vinorelbine Ditartrate
Her2-Receptor Negative Breast Cancer
Wang JiayuP3B (62)
Cis-Diamminedichloroplatinum Ii
Her2-Receptor Negative Breast Cancer
Peking University First HospitalP3B (61)
Eribulin
Her2-Receptor Negative Breast Cancer
Sun Yat-sen UniversityP2B (61)
c105
Her2-Receptor Negative Breast Cancer
University of WashingtonP2B (60)
cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine
Her2-Receptor Negative Breast Cancer
University of WashingtonP2B (60)
Cyclophosphamide
Her2-Receptor Negative Breast Cancer
George Washington UniversityP3B (60)
Eribulin Monomethanesulfonate
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P3B (60)
Olaparib
Her2-Receptor Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical UniversityP3B (60)
Rivoceranib
Her2-Receptor Negative Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.P3B (60)
Sry-Box Transcription Factor 2
Her2-Receptor Negative Breast Cancer
University of WashingtonP2B (60)
Trastuzumab
Her2-Receptor Negative Breast Cancer
Fudan UniversityP3B (60)
Yb-1
Her2-Receptor Negative Breast Cancer
University of WashingtonP2B (60)
Fludeoxyglucose
Her2-Receptor Negative Breast Cancer
University of WashingtonP2B (57)
Methotrexate
Her2-Receptor Negative Breast Cancer
Fudan UniversityP4B (57)
Famitinib
Her2-Receptor Negative Breast Cancer
Fudan UniversityP3B (56)
Fluzoparib
Her2-Receptor Negative Breast Cancer
Fudan UniversityP3B (56)
Niraparib
Her2-Receptor Negative Breast Cancer
Dantari, Inc.P3B (56)
Veliparib
Her2-Receptor Negative Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityP2CCC (55)
Alpelisib
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P2CCC (54)
Adebrelimab
Her2-Receptor Negative Breast Cancer
Fudan UniversityP2CCC (53)
Binimetinib
Her2-Receptor Negative Breast Cancer
National Cancer Institute (NCI)P2CCC (53)
Ceralasertib
Her2-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterP2CCC (53)
Showing 1 to 50 of 186 assets
PreviousPage 1 of 4Next